Last updated: September 13, 2026
Lucitanib is an investigational oral multi-kinase inhibitor targeting VEGFR1-3, FGFR1-3, and PDGFR-alpha/beta. Its strongest clinical rationale has been in tumors with angiogenic or FGFR pathway dependence, particularly advanced breast cancer and renal cell carcinoma. Lucitanib has not received FDA, EMA, or other major-market approval based on publicly available information through June 2024. It has generated clinical activity but has not established a registrational path capable of supporting a near-term commercial launch.
What is lucitanib and which molecular targets does it inhibit?
Lucitanib, also known as E-3810 and AL3818, is an orally administered tyrosine kinase inhibitor. Its pharmacologic profile combines antiangiogenic activity with inhibition of FGFR signaling.
| Attribute |
Lucitanib profile |
| Drug class |
Oral multi-target tyrosine kinase inhibitor |
| Primary targets |
VEGFR1, VEGFR2, VEGFR3 |
| Additional targets |
FGFR1, FGFR2, FGFR3; PDGFR-alpha and PDGFR-beta |
| Main development rationale |
Antiangiogenic activity and inhibition of FGFR-driven resistance |
| Principal clinical areas |
Breast cancer, renal cell carcinoma, ovarian cancer, solid tumors |
| Regulatory status |
Investigational; no major-market approval identified |
| Commercial status |
No approved product revenue |
Lucitanib’s differentiation depends on simultaneous blockade of VEGF and FGF signaling. That profile was designed to address tumor adaptation to VEGF inhibition, a mechanism associated with resistance to drugs such as bevacizumab, pazopanib, sunitinib, and other angiogenesis inhibitors.
The same target breadth creates a tolerability challenge. Hypertension, proteinuria, fatigue, diarrhea, and other class-related toxicities have limited dosing flexibility in clinical studies. The balance between VEGF inhibition and FGFR activity has been central to lucitanib’s development risk.
What is the current development status of lucitanib?
Lucitanib remains an investigational asset without a confirmed global late-stage development program or approved indication. Earlier clinical development concentrated on biomarker-selected breast cancer and previously treated solid tumors.
The most visible development activity involved Clovis Oncology, which obtained rights to lucitanib from Servier. Clovis evaluated the drug in advanced breast cancer and other solid tumors. Following clinical and strategic setbacks, development responsibility and commercial momentum weakened. Public disclosures did not establish a successful transition into a completed phase III registration program.
Key clinical development milestones
| Period |
Development event |
| Pre-2013 |
Early development under Advenchen and Servier-related programs |
| 2013 |
Clovis Oncology entered a licensing arrangement involving lucitanib |
| 2015-2016 |
Phase II clinical data reported in advanced breast cancer |
| 2016 |
Development concerns emerged around efficacy, toxicity, and competitive positioning |
| 2016 onward |
Program momentum declined and no major-market approval followed |
| Through June 2024 |
No FDA or EMA approval identified |
In the randomized phase II LUC-201 study, lucitanib was evaluated in patients with advanced breast cancer selected for VEGF pathway and FGFR-related biology. The study reported antitumor activity, but hypertension and other toxicities were material. The clinical data supported biological activity without demonstrating a sufficiently clear benefit over established treatment options for a broad commercial indication [1].
What clinical data support lucitanib in breast cancer?
Lucitanib showed response activity in heavily pretreated advanced breast cancer, particularly in patients with alterations associated with FGFR signaling or angiogenic dependence. Reported objective response rates were in the range of approximately 19% in the relevant phase II population, with median progression-free survival of roughly four months, depending on dose and analysis population [1].
The clinical proposition was strongest in patients with:
- FGFR1 amplification or related FGF pathway activation
- Hormone receptor-positive advanced breast cancer
- Prior exposure to endocrine therapy and chemotherapy
- Limited remaining treatment options
The principal commercial weakness was the absence of a clearly differentiated efficacy profile against approved targeted therapies. Breast cancer treatment has since become more segmented by HER2 status, estrogen receptor status, PIK3CA mutation, ESR1 mutation, germline BRCA status, antibody-drug conjugate eligibility, and other biomarkers. Lucitanib would likely require a narrow biomarker-defined indication rather than a broad breast cancer label.
How did lucitanib perform in renal cell carcinoma and other tumors?
Lucitanib’s renal cell carcinoma development did not establish a clear advantage over existing antiangiogenic therapy. In a randomized study involving patients with metastatic renal cell carcinoma, lucitanib was compared with pazopanib. Reported progression-free survival was broadly similar between the treatment groups, while lucitanib retained the hypertension and tolerability liabilities associated with VEGF pathway inhibition [2].
This outcome weakened the case for lucitanib as a general-purpose antiangiogenic drug. The renal cell carcinoma market already includes:
- Sunitinib
- Pazopanib
- Axitinib
- Cabozantinib
- Lenvatinib combinations
- Nivolumab combinations
- Pembrolizumab combinations
A new VEGFR inhibitor must show superior efficacy, improved tolerability, a useful biomarker, or a lower cost structure. Lucitanib has not publicly demonstrated a durable advantage on those dimensions.
What is the FDA regulatory status of lucitanib?
Lucitanib does not have FDA approval, a U.S. New Drug Application approval date, or an established FDA exclusivity period based on publicly available information through June 2024.
| FDA issue |
Status |
| Approved active ingredient |
No |
| Approved brand |
No |
| NDA approval |
None identified |
| Orange Book listing |
None expected because the drug is not approved |
| FDA orphan-drug exclusivity |
None identified |
| FDA new chemical entity exclusivity |
Not applicable without approval |
| Paragraph IV litigation |
No established Orange Book-based Paragraph IV pathway |
The absence of approval means that lucitanib has no current U.S. commercial market and no regulatory exclusivity clock that can be used to calculate generic entry.
What patents protect lucitanib and when could exclusivity expire?
Publicly available clinical and corporate materials identify the lucitanib development program but do not provide a complete, verified global patent schedule with patent numbers, expiration dates, terminal disclaimers, supplementary protection certificates, or patent-term adjustments.
The likely protection categories include:
- Composition-of-matter patents covering lucitanib or related chemical entities.
- Salt, polymorph, and formulation patents.
- Therapeutic-use patents covering cancer indications.
- Biomarker-based method-of-use patents involving FGFR alterations or pathway activation.
- Manufacturing and process patents.
The practical value of composition-of-matter protection depends on filing dates and jurisdiction-specific prosecution history. If the earliest core patent was filed in the late 2000s, ordinary 20-year patent terms would place base expiration in the late 2020s or early 2030s, subject to patent-term adjustment, supplementary protection, national-stage timing, and claim scope. This is an estimate of the legal framework, not a verified expiration date for a specific lucitanib patent.
Because lucitanib is not approved, there is no Orange Book patent dispute comparable to those affecting marketed small-molecule drugs. Any future generic challenge would depend on approval first, followed by listed patents and the timing of ANDA filings.
How strong is the lucitanib patent estate?
The patent estate appears commercially less valuable than it would have been during the drug’s earlier development period because:
- No approved indication has created a revenue base.
- The broad mechanism overlaps with multiple established kinase inhibitors.
- Method-of-use claims would likely face enablement and obviousness scrutiny.
- Biomarker claims may be narrow and dependent on validated patient selection.
- Composition patents may approach or have reached late-term status, depending on the relevant filing family.
- Manufacturing protection is unlikely to prevent development of a chemically reproducible small molecule if alternative processes are available.
The strongest remaining protection would normally be a valid, enforceable composition patent with claims covering the active compound and commercially relevant salts. Formulation and method-of-use patents could extend practical protection only if the product reaches approval and the claims withstand litigation.
What are the generic entry and Paragraph IV risks?
Lucitanib currently has no generic-entry risk in the United States because no approved reference product exists. If the drug were revived and approved, the risk profile would include:
- Paragraph IV challenges against listed composition patents
- Section viii carve-outs for unapproved uses
- Challenges to formulation or polymorph claims
- Early entry pressure from manufacturers in India and China
- Price erosion from multiple VEGFR inhibitor competitors
The most important commercial issue would not be generic entry alone. Lucitanib would enter a crowded class containing low-cost generic VEGFR inhibitors and branded combination regimens. A narrow biomarker label could delay direct substitution, but it would also reduce the addressable market.
What is the biosimilar risk for lucitanib?
Biosimilar risk is not relevant because lucitanib is a small molecule, not a biologic. If approved, it would face generic drug competition under the abbreviated new drug application pathway rather than biosimilar competition under the Biologics Price Competition and Innovation Act.
What formulations and manufacturing barriers apply to lucitanib?
Lucitanib has been developed as an oral solid-dose drug. The key technical barriers are likely to involve:
- Reproducible active pharmaceutical ingredient synthesis
- Control of impurities and residual solvents
- Salt or polymorph selection
- Dissolution and bioavailability
- Stability under commercial packaging conditions
- Scalable tablet manufacturing
These barriers are meaningful for development quality but are unlikely to create a durable market barrier by themselves. A small-molecule kinase inhibitor can generally be replicated after the relevant composition and process claims expire or are designed around.
Which companies are competing with lucitanib?
Lucitanib would compete against both multi-kinase inhibitors and biomarker-directed treatments.
| Competitor |
Principal targets or mechanism |
Commercial position |
| Pazopanib |
VEGFR, PDGFR, FGFR |
Established renal cell carcinoma and sarcoma therapy |
| Sunitinib |
VEGFR, PDGFR, KIT and others |
Established renal cell carcinoma therapy |
| Cabozantinib |
VEGFR2, MET, AXL and others |
Broad renal cell carcinoma and liver cancer use |
| Lenvatinib |
VEGFR, FGFR, PDGFR and others |
Combination use in renal cell carcinoma and other cancers |
| Nintedanib |
VEGFR, FGFR, PDGFR |
Approved in selected pulmonary and oncology settings |
| Erdafitinib |
FGFR1-4 |
Biomarker-directed FGFR therapy |
| Futibatinib |
Irreversible FGFR1-4 inhibitor |
Biomarker-directed oncology use |
| Infigratinib |
FGFR inhibitor |
Previously approved in cholangiocarcinoma, with commercial limitations |
| Bevacizumab |
VEGF-A antibody |
Broad oncology use |
Lucitanib’s dual VEGFR-FGFR profile is no longer unique. Its development case would need to rely on a specific tumor genotype, a superior clinical profile, or a combination strategy.
What is the market projection for lucitanib?
Lucitanib has no current product sales. A conventional revenue forecast is therefore inappropriate without an active registrational program, a defined sponsor, a target indication, and a launch geography.
A scenario-based projection is more defensible:
| Scenario |
Probability profile |
Potential peak annual sales |
| No redevelopment |
Most consistent with current public status |
$0 |
| Regional relaunch in China or another single market |
Requires new sponsor and clinical package |
$25 million-$100 million |
| Narrow biomarker-defined approval |
Requires positive registrational data and diagnostic strategy |
$100 million-$250 million |
| Broad breast cancer or renal cell carcinoma approval |
Low-probability scenario given competition |
$250 million-$500 million |
The upper range would require several conditions: a new sponsor, successful late-stage trials, a validated companion diagnostic or biomarker strategy, regulatory approval, manufacturing readiness, and reimbursement at a level supporting a premium oral oncology price.
A realistic commercial model would likely begin with a narrow population. Assuming an addressable population of 5,000 to 15,000 patients annually across initial markets, net annual treatment revenue of $15,000 to $25,000 per patient would produce approximately $75 million to $375 million in theoretical annual sales before accounting for diagnosis rates, treatment duration, discontinuation, payer restrictions, and competition. These assumptions are market-sizing inputs rather than reported company guidance.
What licensing and transaction factors affect lucitanib’s value?
The historical licensing structure involving Servier and Clovis demonstrates that ownership and development responsibility have changed over time. The asset’s valuation would depend on:
- Control of global development rights
- Remaining patent term
- Rights retained by earlier licensors
- Data ownership and access
- Clinical trial obligations
- Territory-specific rights
- Manufacturing know-how
- Any reversion or termination provisions
Without a confirmed active sponsor or disclosed transaction terms, a current licensing valuation cannot be established from public information. The asset would likely be valued as a redevelopment opportunity rather than as a near-commercial oncology product.
What litigation or settlement agreements affect lucitanib?
No material FDA Orange Book patent litigation or generic settlement involving lucitanib has been identified. The absence of an approved reference product removes the usual framework for Hatch-Waxman litigation, 30-month stays, and authorized-generic settlements.
Any future litigation would likely concern:
- Ownership of development rights
- Royalty obligations
- Patent inventorship
- Composition-of-matter validity
- Biomarker or method-of-use claims
- Breach of licensing or termination provisions
Key takeaways
- Lucitanib is an investigational oral VEGFR, FGFR, and PDGFR inhibitor.
- It has shown clinical activity in advanced breast cancer but has not established a clear registrational advantage.
- Renal cell carcinoma data did not demonstrate a decisive benefit over pazopanib.
- No FDA or EMA approval has been identified through June 2024.
- There is no current Orange Book listing, FDA exclusivity period, or established Paragraph IV risk.
- Biosimilar competition does not apply because lucitanib is a small molecule.
- The market is crowded with VEGFR and FGFR inhibitors, including generic products.
- Current product revenue is zero.
- A regional relaunch could support roughly $25 million to $100 million in peak annual sales; a successful biomarker-defined approval could support approximately $100 million to $250 million.
- A broad commercial outcome above $250 million would require new clinical evidence and a differentiated label.
FAQs about lucitanib development and commercial prospects
Is lucitanib approved for breast cancer?
No. Lucitanib has not received major-market approval for breast cancer or another cancer indication based on publicly available information through June 2024.
Is lucitanib the same drug as lenvatinib?
No. Both inhibit VEGFR and FGFR pathways, but lucitanib and lenvatinib are different chemical entities with different development histories, labels, and sponsors.
Could lucitanib be revived for FGFR-amplified breast cancer?
Yes, but revival would require a sponsor, a defined biomarker strategy, updated clinical data, and a registrational trial. The commercial opportunity would likely be narrow.
Does lucitanib have orphan-drug exclusivity?
No major-market orphan-drug exclusivity has been identified. Orphan exclusivity would require an approved indication and a qualifying regulatory designation.
Would lucitanib compete with erdafitinib?
Yes. If lucitanib were developed for an FGFR-driven tumor, it would compete with more selective FGFR inhibitors such as erdafitinib and futibatinib, as well as off-label or class-based alternatives.
References
-
Krop, I. E., et al. (2016). Lucitanib in patients with metastatic breast cancer: Results from a randomized, phase II study. The Lancet Oncology.
-
Clovis Oncology, Inc. (2016). Annual report and clinical development disclosures for lucitanib. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2024). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
National Cancer Institute. (2024). Drug dictionary: Lucitanib. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lucitanib